Olmesartan

Table of contents

• What is olmesartan?
• How does olmesartan work?
• Which conditions is it used or studied for?
• How is olmesartan given?
• What do the clinical trials show?
• What side effects are known?

What is olmesartan?

Olmesartan is a medicine from the class of drugs called angiotensin II receptor blockers (ARBs). It is a chemically synthesised substance. Olmesartan is authorised as a medicine and is available in the European Union, where it is marketed under the name olmesartan medoxomil.^[2] In the clinical trial described in the registry data, olmesartan appears as a comparator drug, meaning it is used as a reference treatment rather than being the main experimental medicine.^[1]

How does olmesartan work?

Olmesartan works by blocking the action of a hormone called angiotensin II. Angiotensin II normally causes blood vessels to narrow and promotes the release of another hormone that raises blood pressure. By blocking the receptor that angiotensin II binds to, olmesartan allows blood vessels to relax and widen, which lowers blood pressure and reduces the workload on the heart. This mechanism is shared by all ARBs and is the basis for their use in conditions such as high blood pressure and heart failure.

Which conditions is it used or studied for?

• High blood pressure (hypertension) — olmesartan is authorised for treating raised blood pressure, helping to reduce the risk of complications such as stroke and heart attack.
• Heart failure — in the registered trial, olmesartan is included as one of several guideline-directed medical therapies being evaluated for optimising treatment in patients with heart failure, with a particular focus on differences between men and women.^[1]

How is olmesartan given?

Olmesartan is taken by mouth as tablets. The product information lists an oral route of administration, and a 20 mg tablet strength is available.^[2] In the trial, olmesartan is listed at two dose strengths, 20 mg and 40 mg, for oral use.^[1]

What do the clinical trials show?

One registered clinical trial includes olmesartan as a comparator. This is a Phase 3 trial with 368 participants, currently authorised.^[1] The trial is not designed to test olmesartan itself; instead, it investigates whether a structured programme of up-titrating guideline-directed medical therapy (GDMT) — a group of life-saving heart failure medicines — improves outcomes in women with heart failure compared with usual care. Olmesartan is one of many drugs that may be part of that therapy.

The trial has two parts. The retrospective part describes current prescribing patterns of GDMT nationally and examines inequalities related to sex. The prospective part randomly assigns women with heart failure to either up-titration of GDMT or usual care, then follows them for 12 months.^[1]

The main outcomes measured include all-cause mortality within one year, readmission to hospital for heart failure, or worsening heart failure. The trial also looks at quality of life, adherence to medication (defined as stopping or reducing the dose), and side effects.^[1]

What side effects are known?

The supplementary source provided does not list side effects for olmesartan. The trial record mentions that side effects are one of the outcomes being measured in the prospective part of the study, but specific side effects are not described in the available data.^[1]